Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avedro
Waltham, Massachusetts, USAavedro.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
Avedro is an ophthalmic pharmaceutical and medical device company that specializes in the treatment of corneal diseases and refractive conditions. The company is best known for developing the first and only FDA-approved corneal cross-linking (CXL) system, which utilizes the KXL System in conjunction with Photrexa (riboflavin 5’-phosphate ophthalmic solution). This therapeutic approach is designed to strengthen the cornea and halt the progression of keratoconus and corneal ectasia. Following its acquisition by Glaukos Corporation in 2019, Avedro's technology has become a cornerstone of Glaukos's corneal health franchise, with ongoing research into photorefractive intrastromal cross-linking (PiXL) for refractive correction.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
Beyond the preview
Go deeper on Avedro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avedro.